Genghis is a Senior Advisor to Abingworth having previously been a Partner and focusing on exits of venture investments via mergers and acquisitions and IPOs. Genghis’s board positions included Avillion, GenSight Biologics, Healthcare Brands International, Nouscom, Novexel, Solexa, Synosia, Syntaxin and Wilson Therapeutics.
Genghis joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London, responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys from 2001 to 2003. Before joining Equity Research at CSFB, he worked for CSFB’s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia and holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School.
